Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL970730 | 0.97 | ALDH1A1 (0.32) | ALDH1A1TSHR | |
| SCHEMBL9108099 | 0.97 | ALDH1A1 (0.32) | ALDH1A1TSHR | |
| SCHEMBL6751593 | 0.97 | ALDH1A1 (0.32) | ALDH1A1TSHR | |
| SCHEMBL4429606 | 0.97 | ALDH1A1 (0.32) | ALDH1A1TSHR | |
| SCHEMBL29105368 | 0.83 | TSHR (0.40) | ALDH1A1TSHRTDP1 | |
| SCHEMBL5323576 | 0.81 | — | — | |
| SCHEMBL1446445 | 0.80 | ALDH1A1 (0.35) | ALDH1A1TSHRTDP1 | |
| SCHEMBL8665942 | 0.79 | ALDH1A1 (0.33) | ALDH1A1TSHRTDP1 | |
| SCHEMBL15541793 | 0.79 | ALDH1A1 (0.33) | ALDH1A1TSHRTDP1 | |
| SCHEMBL11696701 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6703497-B1 | SURFACE MODIFIED BY HAVING HYDROXYL FUNCTIONAL GROUPS PRESENT AT THE SURFACE ETHERIFIED BY ORGANIC COMPOUND COMPRISING SILYLATING AGENT, ISOCYANATE, HALOGENATED ALKYLATING AGENT, ALKYLENE OXIDE, OR GLYCIDYL COMPOUND | RHODIA CHIMIE (FR) | 2004-03-09 | — | — | US | claimed |
| EP-4736861-A1 | ORAL COMPOSITION CONTAINING INORGANIC POROUS BODY | Tanabe Pharma Corporation (JP) | 2026-05-06 | — | — | EP | disclosed |
| US-12421334-B2 | Hybrid supported metallocene catalyst and method of preparing polypropylene using the same | LG CHEM, LTD. (KR) | 2025-09-23 | — | — | US | disclosed |
| US-20250091263-A1 | Low-Pore Pellets and Methods for Producing Molded Body | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2025-03-20 | — | — | US | disclosed |
| US-12186947-B2 | Low-pore pellets and method for producing molded body | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2025-01-07 | — | — | US | disclosed |
| WO-2025005149-A1 | ORAL COMPOSITION CONTAINING INORGANIC POROUS BODY | 田辺三菱製薬株式会社 | 2025-01-02 | — | — | WO | disclosed |
| US-12180344-B2 | Cellulose nanofiber-containing aqueous dispersion | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2024-12-31 | — | — | US | disclosed |
| US-20240328481-A1 | Cellulose-containing Gear | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2024-10-03 | — | — | US | disclosed |
| EP-3786215-B1 | CELLULOSE NANOFIBER-CONTAINING AQUEOUS DISPERSION AND CELLULOSE NANOFIBER-CONTAINING RESIN COMPOSITION | ASAHI CHEMICAL IND (JP) | 2024-09-25 | — | — | EP | disclosed |
| US-20240270948-A1 | RESIN COMPOSITION | MITSUI CHEMICALS, INC. (JP) | 2024-08-15 | — | — | US | disclosed |
| EP-2468798-B1 | SOLID ELECTROLYTE MEMBRANE FOR FUEL CELL AND PROCESS FOR PRODUCING SAME | CENTRAL GLASS CO LTD (JP) | 2017-03-08 | — | — | EP | disclosed |
| US-20160089334-A1 | POROUS METAL OXIDE PARTICLES, PRODUCTION METHOD THEREOF AND APPLICATION THEREOF | MITSUI CHEMICALS, INC. (JP) | 2016-03-31 | — | — | US | disclosed |
| EP-3000785-A1 | METAL OXIDE POROUS PARTICLES, METHOD FOR PRODUCING SAME, AND USE OF SAME | Mitsui Chemicals, Inc. (JP) | 2016-03-30 | — | — | EP | disclosed |
| US-9150422-B2 | Porous metal oxide, method for producing the same, and use of the same | MITSUI CHEMICALS, INC. (JP) | 2015-10-06 | — | — | US | disclosed |
| US-8445551-B2 | Solid electrolyte membrane for fuel cell and process for producing same | CENTRAL GLASS COMPANY, LTD. (JP) | 2013-05-21 | — | — | US | disclosed |
| EP-2468798-A1 | SOLID ELECTROLYTE MEMBRANE FOR FUEL CELL AND PROCESS FOR PRODUCING SAME | Central Glass Company, Limited (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-20120142791-A1 | Solid Electrolyte Membrane for Fuel Cell and Process for Producing Same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2012-06-07 | — | — | US | disclosed |
| EP-2407427-A1 | NOVEL POROUS METAL OXIDE, PROCESS FOR PRODUCING SAME, AND USE OF SAME | Mitsui Chemicals, Inc. (JP) | 2012-01-18 | — | — | EP | disclosed |
| US-20110318249-A1 | NOVEL POROUS METAL OXIDE, METHOD FOR PRODUCING THE SAME, AND USE OF THE SAME | MITSUI CHEMICALS, INC. (JP) | 2011-12-29 | — | — | US | disclosed |
| US-6703497-B1 | SURFACE MODIFIED BY HAVING HYDROXYL FUNCTIONAL GROUPS PRESENT AT THE SURFACE ETHERIFIED BY ORGANIC COMPOUND COMPRISING SILYLATING AGENT, ISOCYANATE, HALOGENATED ALKYLATING AGENT, ALKYLENE OXIDE, OR GLYCIDYL COMPOUND | RHODIA CHIMIE (FR) | 2004-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142791-A1 | Solid Electrolyte Membrane for Fuel Cell and Process for Producing Same | LNPK, KCNJ1, EPCAM | ALDH1A1 2851/4885TSHR 4140/4885TDP1 4558/4885 |
| US-20160089334-A1 | POROUS METAL OXIDE PARTICLES, PRODUCTION METHOD THEREOF AND APPLICATION THEREOF | TOMM40, TMEM70, TOMM70 | ALDH1A1 4852/4885TSHR 4124/4885TDP1 4382/4885 |
| US-12421334-B2 | Hybrid supported metallocene catalyst and method of preparing polypropylene using the same | PMS2, POP1, POLA1 | ALDH1A1 2112/4885TSHR 4637/4885TDP1 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.